Replies to post #248976 on Elite Pharmaceuticals Inc (ELTP)

[Goodtimes93]

Views of the valuation aside. Doc Google search provides convenient facts to support valuations though misses the big ones (eg share count, seqox odds of approval decreased, competition increased, stagnant revenue growth).

[Couch]

Don't forget that dilution has caused an increase of 75% outstanding share count.

Don't forget that is total and utter BS on the increase in share count percentage. The outstanding shares have increased not even 50% since the valuation was done. The share count was over 500 million - 568 million to be precise.

[no2koolaid]

I just love to cut and paste an old response of mine to the same argument about share count increases...

Which is why we need to take a look at some very clear and irrefutably non-subjective numbers that I have presented previously:

•For the fiscal year 2014, Elite had revenues of $4,601,376
•For the fiscal year 2016, Elite had revenues of $12,498,332
This is about a 2.7X increase over two years

But there is more worth considering and that requires a little math…
With 2014 revenues of $4,601,376 and total diluted shares of 526,880,118, the simple math is revenues divided by diluted shares. For 2014 the ratio of revenues per share is .0087. In 2016, Elite had revenues of $12,498,332 and a current total diluted shares (including Nasrat’s conversion from preferred to common) of 900,436,295. For 2016 the ratio of revenues per share is .01388.
The calculation is .01388 (2016 revenues versus diluted shares) divided by .0087 (2014 revenues versus diluted shares). The answer is a 1.6X increase in revenues versus diluted shares. To be clear if it is not, that is a resounding improvement. This is not debatable, nor amenable to some technical analysis, nor subjective in its interpretation…that is what we call irrefutable FACT!

Now, I drop the mic...

[NASDAQ2020]

Dilution is coming to an end:

Immediate Release NDA ADF labeled opiod,
a generic ER ADF labeled Oxycodone,
a generic ADF Embeda® ,
a generic ADF reformulated OxyContin® ,
a generic ADF Troxyca®,
a generic ADF Opana®,
24 hour NDA Oxycodone, and a
Undisclosed drug or two